Patents by Inventor Catherine R. O'Riordan

Catherine R. O'Riordan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
    Patent number: 6569426
    Abstract: Viruses are modified by coupling a polymer such as polyethylene glycol to obtain polymer-modified viruses that can exhibit reduced antigenicity while retaining infectivity, and which may exhibit increased circulation time in vivo. The polymer may be directly covalently attached or indirectly covalently attached via an intermediate coupling moiety to the virus. The polymer may also be indirectly noncovalently attached to the virus via a ligand such as an antibody having specificity for a viral surface component. To prepare the polymer-modified virus, the polymer is activated and coupled to the virus. A preferred activated polymer is tresyl-monomethoxypolyethylene glycol having an average molecular weight of about 5000 daltons. The polymer-modified viruses have utility for therapeutic and diagnostic in vivo applications, and may be used to introduce a transgene into a target cell by infection, or be administered to a subject having a tumor where the polymer-modified virus localizes to the tumor.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: May 27, 2003
    Assignees: Genzyme Corporation, Polymasc Pharmaceuticals
    Inventors: Alan E. Smith, Catherine R. O'Riordan, Gillian E. Francis, Vincent Parkes, Christina Delgado
  • POLYMER-MODIFIED VIRUSES
    Publication number: 20020034498
    Abstract: The present invention relates to polymer-modified viruses, processes for obtaining them and their use. The invention also provides means of attaching polymer molecules to viral particles whereas retaining infectivity of the modified virus.
    Type: Application
    Filed: September 30, 1999
    Publication date: March 21, 2002
    Inventors: ALAN E. SMITH, CATHERINE R. O'RIORDAN, GILLIAN E. FRANCIS, VINCENT PARKES, CHRISTINA DELGADO
  • Nucleic acid delivery vehicles
    Patent number: 6287857
    Abstract: This invention describes a nucleic acid delivery vehicle construct for transfecting and/or infecting a target cell. The construct is made of a delivery vehicle and a bifunctional complex for linking the delivery vehicle to a target cell. The bifunctional complex has a delivery vehicle-binding molecule or fragment (“delivery vehicle-binding portion”), a molecule or fragment thereof that binds to a cell surface molecule on the target cell (“cell surface molecule-binding portion”) and a linker which connects the molecules or fragments.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: September 11, 2001
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, Samuel C. Wadsworth
  • Methods for purifying cystic fibrosis transmembrane conductance regulation
    Patent number: 5939536
    Abstract: The present invention provides a method for purifying a membrane associated protein, e.g., cystic fibrosis transmembrane conductance regulator (hereinafter CFTR) in a functional form. The method involves contacting a membrane-associated protein-membrane fraction complex with a detergent forming a solubilized complex and chromatographically isolating the membrane-associated protein from the solubilized complex in a functional form. The functional form of the purified membrane-associated protein of the present invention preferably is sufficiently pure to allow its introduction into humans for therapeutic purposes.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: August 17, 1999
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, Amy L. Helgerson (Erickson)